Career Enhancement Program (CEP). The goal of the University of Iowa/Mayo Clinic Lymphoma SPORE (SPORE) Career Enhancement Program (CEP) is to provide support (both financial support and extensive mentorship) to highly promising, well-trained scientists interested in pursuing a career in translational lymphoma research. The CEP allows for the support each year of two highly promising investigators who are engaged in SPORE research. The extensive research and training base available at these two institutions as well as the infrastructure of the SPORE provides an outstanding foundation for the SPORE CEP. Successful candidates for the SPORE CEP are typically young investigators (senior postdoctoral fellows about to begin their faculty careers, and young faculty) in translational, multidisciplinary basic, clinical or population-based lymphoma research. On occasion, the CEP is used to assist more experienced, successful investigators interested in shifting their research focus toward translational lymphoma research. The SPORE CEP provides $50,000 for one year ($25,000 from SPORE funds and institutional support of $25,000 from the University of Iowa or Mayo Clinic resources) for each of two awards per year. A second year of support is possible based on progress and successful re-competition. During this most recent funding period (years 11- 15), 10 investigators, including two under-represented minority faculty and four women, received CEP awards and were each supported for 1 year. They all remain active translational investigators in the field of lymphoid malignancies with 9 of the 10 still involved with the SPORE and the 10th a successful investigator at another institution. The CEP awardee (Gupta) from a previous funding period was a co-leader on the current Project 3. In this renewal application, another CEP awardee (Feldman) has become Project 1 co-leader and also Director of the Biospecimens Core. The research of Dr. Z. Yang was important to the proposed Project 1 and Dr. Asmann's research has led to her role in the Biospecimens and Bioinformatics Core in this renewal. During the next funding period, the SPORE will maintain: (1) a stringent candidate selection system that encourages applications from minorities and women; (2) comprehensive trainee guidance by a mentor; (3) support through a scientific mentor group (the Individual Trainee Mentorship Committee) comprised of investigators with expertise in each trainee's area of interest; (4) multi-disciplinary research courses and on-going training activities such as the Multidisciplinary Cancer Seminar Series and Lymphoma Group meetings at both sites; (5) encouragement of collaboration with investigator group meetings at both sites; (6) encouragement of collaboration with investigators at both Iowa and Mayo and (7) opportunities for further research enhancement through the Developmental Research Program and full Projects.

Public Health Relevance

Career Enhancement Program (CEP) The purpose of the Career Enhancement Program (CEP) is to support and mentor young investigators at the junior faculty level so that they can become outstanding translational investigators with a primary focus on lymphoma. The Lymphoma SPORE selects two outstanding candidates each year for the CEP and provides $50,000 per award. Candidate success is enhanced through mentorship and access to the SPORE Core resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097274-19
Application #
9988177
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
19
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
Thompson, Carrie A; Yost, Kathleen J; Maurer, Matthew J et al. (2018) Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol 36:749-756
Naik, Shruthi; Galyon, Gina D; Jenks, Nathan J et al. (2018) Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer. Mol Cancer Ther 17:316-326
Thanarajasingam, Gita; Maurer, Matthew J; Farooq, Umar et al. (2018) Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 183:149-152
Kleinstern, Geffen; Maurer, Matthew J; Liebow, Mark et al. (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73
Saad Aldin, Ehab; McNeely, Parren; Menda, Yusuf (2018) Posterior Reversible Encephalopathy Syndrome on 18F-FDG PET/CT in a Pediatric Patient With Burkitt's Lymphoma. Clin Nucl Med 43:195-198
Link, Brian K; Day, Bann-Mo; Zhou, Xiaolei et al. (2018) Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol :
Ebeid, Kareem; Meng, Xiangbing; Thiel, Kristina W et al. (2018) Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol 13:72-81
Holahan, Heather M; Farah, Ronda S; Fitz, Sara et al. (2018) Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol 57:1314-1319

Showing the most recent 10 out of 387 publications